Fredun Pharmaceuticals Ltd Share Price – BSE

Pharmaceuticals, Small Cap

Net profit of Fredun Pharmaceuticals rose 39.72% to Rs 7.07 crore in the quarter ended March 2025 as against Rs 5.06 crore during the previous quarter ended March 2024. Sales rose 41.15% to Rs 165.44 crore in the quarter ended March 2025 as against Rs 117.21 crore during the previous quarter ended March 2024.

For the full year,net profit rose 33.23% to Rs 20.81 crore in the year ended March 2025 as against Rs 15.62 crore during the previous year ended March 2024. Sales rose 30.33% to Rs 451.71 crore in the year ended March 2025 as against Rs 346.58 crore during the previous year ended March 2024.

Powered by Capital Market - Live News

Fredun Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 30 May 2025, inter alia, have recommended the final dividend of Rs 0.7 per equity Share (i.e. 7%) , subject to the approval of the shareholders.

Powered by Capital Market - Live News

Fredun Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 30 May 2025.

Powered by Capital Market - Live News

Fredun Pharmaceuticals has been awarded a significant tender by the Tamil Nadu Medical Services Corporation (TNMSC) for the supply of generic medicines. The total value of the tender ranges between Rs. 15-18 crore. The supply of these goods is set to commence within the first quarter of FY26 and will extend over a period of 14 months.

Commenting on the Development, Fredun Medhora, Managing Director, said: ?We are thrilled to have been awarded this tender by TNMSC. This achievement reflects our ongoing efforts to deliver quality healthcare solutions and our commitment to serving the needs of the public health sector. We look forward to a successful collaboration with TNMSC and to making a positive impact on the healthcare landscape in Tamil Nadu.

Powered by Capital Market - Live News